Human Ebola virus infection results in substantial immune activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 15, 2015, Pages 4719-4724

  McElroy, Anita K ^a,b   Akondy, Rama S ^b   Davis, Carl W ^b   Ellebedy, Ali H ^b   Mehta, Aneesh K ^b   Kraft, Colleen S ^b   Lyon, G Marshall ^b   Ribner, Bruce S ^b   Varkey, Jay ^b   Sidney, John ^c   Sette, Alessandro ^a   Campbell, Shelley ^a   Ströher, Ute ^a   Damon, Inger ^a   Nichol, Stuart T ^a   Spiropoulou, Christina F ^a   Ahmed, Rafi ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Ebola infection; Human immune response; Immune activation; Plasmablasts; T cells

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CONVALESCENCE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION; BLOOD; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PRE B LYMPHOCYTE; VIROLOGY;

EBOLA VIRUS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PRECURSOR CELLS, B-LYMPHOID; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

EID: 84928026094     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502619112     Document Type: Article

References (29)

1. Sanchez A, Geisbert T, Feldmann H (2007) Filoviridae: Marburg and Ebola Viruses (Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia), 5th Ed.
2. Baize S, et al. (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128(1):163-168.
3. Baize S, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5(4):423-426.
4. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM (2010) Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4(10):e837.
5. Villinger F, et al. (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188-S191.
6. Ansari AA (2014) Clinical features and pathobiology of Ebolavirus infection. J Autoimmun 55:1-9.
7. Geisbert TW, et al. (2000) Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80(2):171-186.
8. Bradfute SB, et al. (2010) Mechanisms and consequences of Ebolavirus-induced lymphocyte apoptosis. J Immunol 184(1):327-335.
9. Gupta M, Spiropoulou C, Rollin PE (2007) Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364(1):45-54.
10. Ksiazek TG, et al. (1999) Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S177-S187.
11. Rowe AK, et al. (1999) Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 179(Suppl 1):S28-S35.
12. Mahanty S, et al. (2003) Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170(6):2797-2801.
13. Bosio CM, et al. (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188(11):1630-1638.
14. Basler CF, Amarasinghe GK (2009) Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 29(9):511-520.
15. Lyon GM, et al.; Emory Serious Communicable Diseases Unit (2014) Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371(25):2402-2409.
16. Miller JD, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28(5):710-722.
17. Precopio ML, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204(6):1405-1416.
18. Lindgren T, et al. (2011) Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol 85(19):10252-10260.
19. Akondy RS, et al. (2009) The yellow fever virus vaccine induces a broad and poly-functional human memory CD8+ T cell response. J Immunol 183(12):7919-7930.
20. Basler CF, et al. (2000) The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 97(22):12289-12294.
21. Sanchez A, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 78(19):10370-10377.
22. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-687.
23. Fink K (2012) Origin and function of circulating plasmablasts during acute viral infections. Front Immunol 3:78.
24. Kreuels B, et al. (2014) A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 371(25):2394-2401.
25. Marzi A, Feldmann H (2014) Ebola virus vaccines: An overview of current approaches. Expert Rev Vaccines 13(4):521-531.
26. Stanley DA, et al. (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge. Nat Med 20(10):1126-1129.
27. Qiu X, et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47-53.
28. Geisbert TW, et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375(9729):1896-1905.
29. Towner JS, Sealy TK, Ksiazek TG, Nichol ST (2007) High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 196(Suppl 2):S205-S212.